PEBP1 and diabetic kidney disease: Studies have found that RKIP can act as a negative regulator of the nuclear factor kappa B (NF-κB) signaling pathway, inhibit its expression, and slow the inflammatory response, which undoubtedly has a protective regulatory effect on DKD [34].